positive in the L. gasseri OLL2716 group compared to that in the placebo group (statistical trend; p = 0.073). The elimination rate for major FD symptoms was 17.3 and 35.3% in the placebo and L. gasseri OLL2716 groups respectively ( p = 0.048). Conclusion: L. gasseri OLL2716 has beneficial effects on FD without H. pylori involvement.
Functional dyspepsia (FD) is a condition with persistent abdominal symptoms affecting mainly the epigastrium. It is believed to originate from the stomach and duodenum despite the absence of an organic, systemic, or metabolic disease that could explain the symptoms. Two FD subtypes have been defined: postprandial distress syndrome (PDS), which is characterized by postprandial fullness and early satiety, and epigastric pain syndrome (EPS), which is characterized by epigastric pain and epigastric burning [1] . FD is diagnosed based on a certain number of subjective symp-toms due to the absence of widely applicable biomarkers [2] . No treatment allowing for a complete cure has yet been fully established, and in many cases, symptoms disappear and recur repeatedly in the long term, causing a marked deterioration in the quality of life [3] .
The etiopathology of FD remains unclear. However, the condition often overlaps with disorders such as irritable bowel syndrome (IBS) and gastroesophageal reflux disease; the etiopathologies of these conditions are believed to have commonalities. Stress is known to be involved in these conditions, and findings in research studies on brain-gut interactions, which involve the central nervous system, have suggested that various symptoms might be due to motor function abnormalities and visceral hypersensitivity mediated by brain-gut interactions [4, 5] . In addition, Helicobacter pylori -associated FD [6] and post-infectious FD [7] have been reported, and an association between FD and abnormalities of gastrointestinal mucosal immunity has attracted attention.
Probiotics are lactic acid bacteria that are beneficial for health and they have been reported to be effective in the treatment of IBS [8, 9] . However, it does not necessarily follow that probiotics improve FD as well as IBS. The ameliorating effect of probiotics on IBS is believed to result in improved mucosal permeability by reducing abnormalities of the intestinal microbiota [9] [10] [11] . Meanwhile, the duodenum, a site of few bacteria, has recently been a focus of attention as an organ involved in the onset of FD [12, 13] . Thus, probiotics could improve H. pyloriassociated dyspepsia through an inhibitory effect on H. pylori ; however, it remains unclear whether probiotics can improve FD symptoms in H. pylori -uninfected individuals. Meta-analyses have shown the effectiveness of H. pylori eradication therapy to be low, with the number of patients required to achieve improvement in one person (the number needed to treat) to be 14 [14] . This suggests that H. pylori infection is just one of the factors causing FD symptoms, and we believe it is important to clinically evaluate whether probiotics are effective against H. pylori -uninfected FD individuals. In addition, only a few reports have suggested thus far that probiotics might be effective for FD [15] [16] [17] [18] . Therefore, we performed a double-blind, parallel-group, placebo-controlled, randomized, controlled trial (RCT) with L. gasseri OLL2716 in H. pylori -uninfected FD individuals.
Materials and Methods

Study Design
A double-blind, parallel-group, placebo-controlled RCT was performed, with participants assigned to one of 2 groups: the L. gasseri OLL2716 group or the placebo group ( Fig. 1 ) . The study was performed between July 22, 2014 and December 1, 2014, at the Sekino Clinical Pharmacology Clinic (Tokyo, Japan). Approval for the study was obtained following a review of its ethical and scientific validity by the Ethics Committee of Meiji Co., Ltd., as well as by the Ethics Committee of HUMA R&D Co., Ltd. (Tokyo, Japan). In compliance with ethical principles based on the Declaration of Helsinki and ethical guidelines for epidemiological research, the purpose and contents of this study were fully explained to the participants before participation, and written informed consents were obtained from all the participants.
Participants
Japanese individuals, between the ages of 20 and 64 years, with complaints involving the epigastric region and who had not received any treatment were recruited. At the screening test (visit 1), 94 recruited individuals were confirmed to have had 1 or more of the 4 symptoms of dyspepsia defined according to Rome III criteria (bothersome postprandial fullness, early satiety, epigastric pain, and epigastric burning) during the preceding 6-month period (or more), with such symptoms occurring regularly during the last 3-month period [1] . In addition, recruited individuals were confirmed to be H. pylori -negative. Individuals who met the selection criteria and did not meet any of the exclusion criteria were considered eligible. The exclusion criteria were as follows: consultation with medical institutions during the 6-month period prior to the study for diabetes or disorders of the gastrointestinal tract; medical treatment for dyspepsia symptoms during the 6-month period preceding the study; oral treatments using low-dose aspirin, as well as regular use of nonsteroidal anti-inflammatory agents during the 6-month period preceding the study; suspected diabetes, gastrointestinal disorders, or severe renal impairment on the basis of blood tests (hematology and biochemistry), medical examination by interview, and physical examination at the time of the screening; moderate or severe heartburn or reflux symptoms during the 3-month period preceding the study; history of receiving H. pylori eradication therapy; ingestion of lactic acid bacteria-containing food products 3 times or more per week during the 3-month period preceding the screening tests. This trial was conducted without an endoscopy; however, we confirmed the absence of organic disease, which could be related to dyspepsia symptoms, by confirming the participants to be H. pylori-uninfected, and by excluding the participants with alarming symptoms as well as those who had received medical treatment at risk for organic gastrointestinal disease. In Japan, it was reported that only 9% of patients with dyspepsia symptoms had organic disease by the endoscopy examination [19] . Since healthy participants were screened among the general population who had not received medical treatment for the dyspepsia symptoms, we did not perform endoscopy on them considering the participant's burden.
H. pylori Screening Serum anti-H. pylori antibody titers were measured using the sandwich ELISA method (E plate; Eiken), and serum pepsinogen levels (serum PG) were measured using the latex agglutination test (L-Z test; Eiken). It was reported that the sensitivity and specificity of serum PG levels for detecting H. pylori -positive subjects were both over 90% among Japanese, using PG II ≥ 12 and PG I/II ratio ≤ 4.5 for the cutoff value [20] . Thus, individuals who met the following 2 conditions at the same time were considered H. pylorinegative: PG II <12 with a PG I/II ratio ≥ 4.5, and serum anti-H. pylori antibody levels <3 U/mL.
Study Protocol
For individuals considered to be eligible for the study at the time of the screening, confirmation was obtained once again during the baseline period, ensuring that the selection criterion regarding the 4 symptoms of dyspepsia was satisfied. A third-party institution (Nihonbashi Egawa Clinic, Tokyo, Japan) then assigned the pooled subjects collectively and randomly into two groups. Stratified randomization was performed to balance the gender and the FD subtype across the 2 groups. In the placebo group, participants were instructed to ingest one unit (85 g) of yogurt made from a mixture of raw milk, dairy products, sugar, a sweetener (stevia), and raw water, fermented with Lactobacillus delbrueckii subsp. bulgaricus and Streptococus thermophiles . In the L. gasseri OLL2716 group, participants were instructed to ingest L. gasseri OLL2716-containing yogurt that was made by addition of L. gasseri OLL2716 to the same type of yogurt as above (amount of L. gasseri OLL2716 per unit of yogurt: 10 9 CFU or higher). The nutrients per unit (85 g) of placebo and L. gasseri OLL2716-containing yogurt were as follows: energy, 68 kcal; protein, 2.9 g; lipids, 2.6 g; carbohydrates, 8.3 g; sodium, 37 mg; and calcium, 102 mg. Verifications were performed to confirm that the test food products were indistinguishable based on their flavor and external appearance, and participants were instructed to ingest one unit (85 g) of the assigned test food product per day for 12 weeks. No restriction was imposed regarding the time of intake.
Assessments
Global Assessment
As a global participant assessment, a questionnaire determining the participant's impression of the overall effect of the 12-week intake of the test food product on gastric symptoms was completed. The participants were instructed to answer the question, "How have your overall gastric symptoms been during the past week, compared with your symptoms during the baseline period preceding the intake of the food product?," on a 7-point Likert scale as follows [21, 22] : (1) extremely improved compared with the baseline period; (2) improved compared with the baseline period; (3) slightly improved compared with the baseline period; (4) no change; (5) slightly aggravated compared with the baseline period; (6) aggravated compared with the baseline period; and (7) extremely aggravated compared with the baseline period.
Individual Symptom Scores A questionnaire regarding the severity of individual FD symptoms and accompanying symptoms was completed during the baseline period and after 4, 8, and 12 weeks of test food intake. Participants rated the severity of symptoms (heartburn, epigastric pain, epigastric burning, postprandial fullness, epigastric bloating, early satiety, belching, nausea, abdominal bloating, and reflex feeling of gastric acid) occurring in the prior week on a 7-point Likert scale as follows [23, 24] : (1) none (absence of symptoms); (2) extremely mild (symptoms could be entirely ignored); (3) mild (symptoms easily tolerated); (4) moderate (symptoms noticed by the patient, but did not affect daily activities); (5) moderate-to-severe (symptoms occasionally limited daily activities); (6) severe (symptoms often limited daily activities); and (7) extremely severe (considerable interference with daily activities, often requiring rest).
Symptom Elimination Rates
The disappearance of a dyspepsia symptom was defined as the absence of an individual FD symptom based on the Likert scales mentioned above. The elimination rate for the 4 major FD symptoms [24] was calculated for each group using the following formula: the number of participants who experienced the disappearance of symptoms / the number of participants in the group × 100. The elimination rate for PDS symptoms was calculated for each group using the following formula: the number of participants classified as PDS (during the baseline period) who experienced the simultaneous disappearance of postprandial fullness and early satiety / the number of participants classified as PDS (during the baseline period) in the group × 100. The elimination rate for EPSlike symptoms was similarly calculated for each group. Secondary endpoints: (1) the elimination rate for the 4 major symptoms of FD was assessed during the baseline period and after 4, 8, and 12 weeks of test food intake. In addition, the elimination rate for each FD subtype (PDS, EPS) symptom was assessed by performing a stratified analysis. (2) The individual FD symptom scores and those of the accompanying symptoms were assessed during the baseline period and after 4, 8, and 12 weeks of test food intake.
Safety Assessment Adverse events and side effects occurring during the study period were assessed in both groups for participants who had ingested the test food product at least once.
Statistical Analysis
We previously reported that yogurt containing L. gasseri OLL2716 significantly suppressed the postprandial fullness in H. pylori -infected subjects when compared to the condition between the baseline period and after 12 weeks of test food intake. However, the placebo yogurt did not significantly suppress postprandial fullness [15] . Based on the data from previous studies on L. gasseri OLL2716, the sample size was estimated by an analysis of covariance. Thus, a sample size of 108 was estimated to be sufficient to detect (detection rate, 80%) a potential ameliorating effect on postprandial fullness in comparison to the placebo group, with the significance level set to less than 5%.
Group comparisons at baseline were performed using Fisher's exact test for categorical variables and unpaired Student t or Wilcoxon rank sum tests for continuous variables. Statistical analyses of the primary endpoint and individual symptom scores were performed using Wilcoxon rank sum tests. Statistical analyses of the symptom elimination rate were performed using Fisher's exact tests. The significance level was set to 5% on both sides. Statistical analyses were performed using SPSS statistics 19 for Windows (SPSS Inc., Chicago, IL, USA). In accordance with a study execution plan prepared beforehand, an analysis of effectiveness was performed against the per-protocol (PP) population.
Results
Participant Selection and Characteristics
Screening tests were performed in 304 Japanese individuals between the ages of 20 and 64 years who had epigastric complaints and had not received any treatment ( Fig. 2 ) . Randomization was performed on 116 individu- 96 als (58 individuals in each group), and 112 participants completed the study. However, 6 of those who completed the study were found to have taken prohibited oral medications (antibiotics). Therefore, the PP population consisted of 106 individuals ( L. gasseri OLL2716 group, 54 individuals; placebo group, 52 individuals). Among the PP population (27 male, 79 female; mean age 42.8 ± 9.0 years), a total of 81 individuals were classified as PDS, while none of the participants met all the Rome III criteria defining EPS; thus, EPS-like dyspepsia accounted for 38 individuals. In the baseline characteristics of participants in the PP population, no significant group differences were found ( Table 1 ) .
Primary Endpoint
Although the participant's impression regarding the overall effects of the 12-week test food intake on the gastric symptoms was more positive in the L. gasseri OLL2716 group compared to that in the placebo group, the difference reached a statistical trend and was not sig- Fig. 3 ). The percentages of individuals who responded that symptoms were "very much aggravated," "aggravated," "slightly aggravated," "unchanged," "slightly improved," "improved," or "very much improved" after the 12-week test food intake were 0, 0, 1.9, 13.5, 53.8, 23.1, and 7.7%, respectively, in the placebo group; and were 0, 0, 0, 7.4, 46.3, 35.2, and 11.1%, respectively, in the L. gasseri OLL2716 group.
Secondary Endpoints Symptom Elimination Rates
As shown in Figure 4 , the elimination rate for the 4 major FD symptoms after the 12-week test food intake was 17.3% in the placebo group and 35.2% in the L. gasseri OLL2716 group, with a statistically significant group difference ( p = 0.048). In addition, as shown in Figure 5 , the elimination rate for PDS symptoms after the 12-week test food intake was 17.8% in the placebo group and 37.5% in the L. gasseri OLL2716 group, with a statistically significant group difference ( p = 0.040). However, the elimination rate for EPS-like symptoms was 31.6% in the placebo group and 36.8% in the L. gasseri OLL2716 group, with no statistically significant difference ( p = 1.000).
Individual FD Symptom Scores and Accompanying Symptom Scores As shown in Figure 6 , compared to the scores in the placebo group, the L. gasseri OLL2716 group showed statistically significant improvements in the symptom scores for postprandial fullness (both 8 and 12 weeks, p = 0.042). In addition, the symptom scores for early satiety tended to improve in the L. gasseri OLL2716 group compared to those in the placebo group (8 weeks, p = 0.088; 12 weeks, p = 0.070). Furthermore, compared to those in the placebo group, the symptom scores for epigastric burning tended to improve in the L. gasseri OLL2716 group (4 weeks, p = 0.086). There were no significant group differences or trends in terms of epigastric pain at any time.
The results regarding the accompanying symptoms of FD are shown in online supplementary karger.com/doi/10.1159/000479000). The symptom scores for epigastric bloating showed a statistically significant improvement in the L. gasseri OLL2716 group compared to those in the placebo group (8 weeks, p = 0.032; 12 weeks, p = 0.017). Compared to those in the placebo group, the symptom scores for heartburn showed a statistically significant improvement in the L. gasseri OLL2716 group after 4 and 8 weeks of test food intake, but not after 12 weeks (4 weeks, p = 0.027; 8 weeks, p = 0.020). Compared to the placebo group, the symptom scores for the reflex feeling of gastric acid displayed a statistical trend for improvement in the L. gasseri OLL2716 group after 4 weeks of test food intake, and showed a significant improvement after 8 weeks (4 weeks, p = 0.088; 8 weeks, p = 0.047).
Safety Assessment
A safety assessment was performed using data from the 115 individuals who had ingested the test food product once or more. Two individuals in the L. gasseri OLL2716 group and 5 individuals in the placebo group experienced adverse events. No significant group differences were found in terms of the incidence of adverse events ( p = 0.438). Confirmation showed no causal relationship between the test food and the adverse events, and none of the adverse events had any side effects.
Discussion
In assessing the effects of interventions against FD, patient-reported outcomes regarding their experience of the disease are important because of the absence of apparent mechanical abnormalities and established biomarkers [23, 25] . The participant's impression regarding the overall effect on gastric symptoms has thus been used as a primary endpoint in FD clinical trials; the intervention effect is easier to understand, as it is inclusive [21, 22] . This study also used this outcome as the primary endpoint. We found that the participant's impression regarding the overall effect on gastric symptoms was more positive in the L. gasseri OLL2716 group compared to that in the placebo group, with the difference reaching a nonsignificant statistical trend ( p = 0.073). Meanwhile, the elimination rate for all 4 major FD symptoms after the 12-week test food intake was significantly higher in the L. gasseri OLL2716 group compared to that in the placebo group ( p = 0.048). The participant's impression as the primary endpoint consisted of the response to the question, "How have your overall gastric symptoms been during the past week, compared with your symptoms during the baseline period preceding the intake of the food product?," which requires the recollection of the symptoms at baseline and includes the influence of symptoms accompanying FD (such as heartburn and belching). Because of this, the participant's impression may have restricted the ability to evaluate FD, reducing the statistical power. In addition, L. gasseri OLL2716-induced improvements were not found for EPS-like symptoms; thus, EPS symptoms might have contributed to the participant's impression to a greater extent, compared to that for PDS symptoms. Moreover, most of the participant's responses in the placebo group were positive regarding the primary endpoint. It is reported that a placebo effect is generally observed in the treatment of FD; however, the use of yogurt as placebo may have provided some improvement to the symptoms of FD. The rela- 
